fb-pixelFeds slam Mylan for misclassifying EpiPen, with “financial consequences” to Medicaid - The Boston Globe Skip to main content

Feds slam Mylan for misclassifying EpiPen, with “financial consequences” to Medicaid


Ed Silverman can be reached at ed.silverman@statnews.com. Follow him on Twitter @Pharmalot. Follow Stat on Twitter: @statnews.